830 Winter St
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
424 articles with ImmunoGen Inc.
ImmunoGen, Inc. announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference.
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification.
ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
ImmunoGen, Inc. announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 14-18, 2018 in Chicago.
2/19/2018Three biotech stocks gained over 25 percent last week.
ImmunoGen gave a pipeline progress report and 2017 operating results last week.
Revenues for the year ended December 31, 2017 were $115.4 million, compared to $48.6 million for the year ended December 31, 2016.
ImmunoGen today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results.
Mr. Arbuckle is replacing Howard Pien, who is stepping down from ImmunoGen’s Board after eight years of service.
ImmunoGen today announced that the first patient has been treated with IMGN632 in a Phase 1 clinical trial of patients with CD123-positive hematological malignancies.
ImmunoGen announced that new data from the Company’s ongoing Phase 1 study of IMGN779, a next-generation CD33-targeting ADC, in patients with relapsed or refractory adult acute myeloid leukemia (AML) were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta.
Revenues for the quarter ended September 30, 2017 were $8.5 million, compared to $7.7 million for the quarter ended September 30, 2016.
ImmunoGen today announced that three abstracts highlighting two of the Company’s experimental ADC therapies, IMGN632 and IMGN779, have been accepted for presentations at the upcoming ASH Annual Meeting to be held December 9-12, 2017, in San Diego.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 3, 2017 to discuss its third quarter 2017 financial results. Management also will provide a brief update on the business.
ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
ImmunoGen, Inc. today announced that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application for IMGN632 in patients with CD123-positive hematological malignancies.
ImmunoGen Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares
ImmunoGen Announces Agreements To Exchange $76.4 Million Of Its 4.50% Convertible Senior Notes Due 2021 For Common Stock